Four States Pass Laws Allowing OTC Ivermectin, More States Pending Legislation - Pharmacy Times
Four states have passed laws allowing over-the-counter (OTC) sales of Ivermectin; additional states are considering similar legislation.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmacies and pharmaceutical manufacturers operating in the affected states. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action is recommended as laws are already in effect in the four states.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Ivermectin can now be sold OTC in four states, with potential for more states to follow.
Who it affects
Pharmacies and pharmaceutical manufacturers operating in the affected states.
What you must do
Review and update inventory and sales practices to include OTC Ivermectin where applicable.
Deadline
Immediate action is recommended as laws are already in effect in the four states.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Feb. 6 Policy Watch: FDA relaxes policy on food color labeling - C&EN
- FDA Announces Seven Participants to PreCheck Pilot Program - pharmexec.com
- Managing Bulk Pharmaceutical Powders in Compounding - pharmacypracticenews.com
- Grace to expand US drug chemical plant - C&EN
- Novo Nordisk FDA Setback Creates Opportunity for Korean CDMOs - Businesskorea